Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qideng Mingmu Capsule is a Traditional Chinese Medicine (TCM) formulation developed by the Chengdu University of Traditional Chinese Medicine for the treatment of diabetic macular edema (DME). The name suggests the inclusion of *Astragalus membranaceus* (Huangqi) and *Erigeron breviscapus* (Dengzhanxihua), which are commonly used in TCM to tonify Qi and promote blood circulation. It is designed to address the underlying pathology of DME by potentially improving retinal microcirculation and reducing vascular permeability. Clinical development is focused on evaluating its safety and efficacy as an oral therapeutic option for patients suffering from vision loss due to diabetic complications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qideng Mingmu Capsule.